| Autor: |
Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira, Marina Borges |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Health Economics Review, Vol 11, Iss 1, Pp 1-13 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2191-1991 |
| DOI: |
10.1186/s13561-021-00332-0 |
| Popis: |
Highlights i. The results obtained in the AC-DHP cohort, which included Pertuzumab as a NeoT, suggest better clinical outcomes compared to the AC-DH group, a confirmation based on real-world data. ii. Some patient profiles seem to be more promising concerning the overall costs for pathological complete response, but the present data does not include a long-term follow-up period, which suggests that interpretations should be performed with caution. iii. Pertuzumab cost estimated represented a great proportion of overall total costs per patient, but further research (including the costs of the whole episode of care) and continuously monitoring (additional RWE) is needed for a more robust cost-effectiveness analysis. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink